Literature DB >> 24322788

Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.

K A Cadoo1, M N Fornier, P G Morris.   

Abstract

Breast cancer is comprised of a number of complex and heterogeneous subtypes with differing clinical behavior and outcomes. In recent years, significant advances have been made in discerning the molecular drivers of this disease, and characterizing distinct subtypes of breast cancer based on gene expression profiles. These advances have begun to translate into greater individualization of treatment for patients. Although these advances have shaped our understanding of the underlying biology of breast cancer, most clinical decisions are currently based on tumor expression of the estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). These biomarkers have prognostic and predictive significance in breast cancer and have important implications for tumor growth and metastatic patterns. In this review, we focus on the three broad phenotypes of breast cancer used in clinical practice; ER/PR positive, HER2 positive and triple negative breast cancer (TNBC), which is characterized by lack of expression of ER, PR and HER2. We discuss the influence of these tumor-related factors as well as histological subtype, on the potential for breast cancer recurrence and patterns of disease spread.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24322788

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  49 in total

1.  Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data.

Authors:  Saber Fallahpour; Tanya Navaneelan; Prithwish De; Alessia Borgo
Journal:  CMAJ Open       Date:  2017-09-25

Review 2.  Disadvantaged neighborhoods and racial disparity in breast cancer outcomes: the biological link.

Authors:  Geetanjali Saini; Angela Ogden; Lauren E McCullough; Mylin Torres; Padmashree Rida; Ritu Aneja
Journal:  Cancer Causes Control       Date:  2019-05-20       Impact factor: 2.506

3.  ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer.

Authors:  Bo Ma; Qianqian Ma; Chunhui Jin; Xiaohong Wang; Guolei Zhang; Huiying Zhang; Harald Seeger; Alfred O Mueck
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 4.  Roles of RUNX in Hippo Pathway Signaling.

Authors:  Antonino Passaniti; Jessica L Brusgard; Yiting Qiao; Marius Sudol; Megan Finch-Edmondson
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Insulin priming effect on estradiol-induced breast cancer metabolism and growth.

Authors:  Peninah M Wairagu; Ai N H Phan; Min-Kyu Kim; Jeongwoo Han; Hyun-Won Kim; Jong-Whan Choi; Ki Woo Kim; Seung-Kuy Cha; Kwang Hwa Park; Yangsik Jeong
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 6.  Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer.

Authors:  Xi Zhang; Nadia Harbeck; Udo Jeschke; Sophie Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-26       Impact factor: 4.553

7.  18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.

Authors:  Gary A Ulaner; Raychel Castillo; Jonathan Wills; Mithat Gönen; Debra A Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-29       Impact factor: 9.236

8.  (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.

Authors:  Gary A Ulaner; Raychel Castillo; Debra A Goldman; Jonathan Wills; Christopher C Riedl; Katja Pinker-Domenig; Maxine S Jochelson; Mithat Gönen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-30       Impact factor: 9.236

9.  Implementation of the 21-gene recurrence score test in the United States in 2011.

Authors:  Julie A Lynch; Brygida Berse; Valentina Petkov; Kelly Filipski; Yingjun Zhou; Muin J Khoury; Michael Hassett; Andrew N Freedman
Journal:  Genet Med       Date:  2016-02-11       Impact factor: 8.822

Review 10.  Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review.

Authors:  Maryam Ghanbari-Movahed; Tea Kaceli; Arijit Mondal; Mohammad Hosein Farzaei; Anupam Bishayee
Journal:  Biomedicines       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.